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SUMMARY 
I  INTRODUCTION 
The Commission's obligations 
Article 4(i) of  Directive 76/768/EEC, as amended by Directive 93/35/EEC, specifies that 
''Member  States  shall  prohibit  the  marketing  of cosmetic  products  containing  ... 
ingredients or combinations of  ingredients tested on animals after 1 January 1998  ... ". 
The ambiguity of the expression "combinations of ingredients" has been resolved as far 
as  the  Commission  is  concerned,  which  considers  that  the  ban  also  covers  finished 
cosmetic products. 
The implementation of this ban is linked to the development of "satisfactory methods to 
replace  animal  testing  ...  scientifically  validated  as  offering  an  equivalent  level  of 
protection for the  consumer". 
With a view to  providing regular information on  how the situation  is  developing  it is 
specified  that  "[t]he  Commission  shall  present  an  annual  report  to  the  European 
Parliament  and the  Council  on  progress  in  the  development,  validation  and legal 
acceptance of  alternative methods to those involving experiments on animals. That report 
shall contain precise data  on  the  number and type  of  experiments related to  cosmetic 
products carried out on animals". 
1994 Report 
A  first  report  was  presented  in  1994.  It  described  interesting  but  limited  results, 
concluding  that  "animal  models  cannot  be  replaced,  though  they  can  contribute  to 
reducing the number of animals used  ... ". However, the outlook was reasonably optimistic 
as regards the validation of  alternative methods for eye irritation, percutaneous absorption, 
phototoxicity/photoirritancy and basic mutagenicity tests. It was also underlined that given 
the current stage of the art it was unlikely that animal tests could be totally replaced in 
toxicity studies for evaluating the systemic risk, i.e. action via the circulatory system on 
the organism in its entirety after percutaneous absorption. 
ll  1995 REPORT 
The objectives of the report and the notion of the potential risk for human health  an~ the 
same as in the 1994 report.  · The players involved in implementing this instrument are: 
the European Commission: DG XI, DG-JRC, DG XXIV, DG XII 
the European industry, represented by COLIPA (the European Cosmetic, Toiletry 
and Perfume Association) 
the American administration and the American Cosmetology Federation, CFTA 
the Japanese administration and the Japanese Cosmetology Federation, JCIA 
the OECD. 
1  Clarification of the validation stages 
Validation is the procedure via which the reliability  and relevance of a  procedure are 
established to a specific end. This process turned out to be more complex than envisaged 
and will take more time than foreseen. It  has been necessary to define more precisely the 
validation stages of the new tests (development of a test and production of a protocol; 
prevalidation;  validation  proper;  objective  and  independent  evaluation  of the  study, 
progress towards legal acceptance). 
2  The initiatives 
The  various  players  have  taken  numerous  initiatives  with  a  view  to  achieving  the 
prescribed objectives. 
DGXI 
DG XI manages Directive  86/609/EEC  on  the  protection of animals  used  for 
experimental  and other scientific purposes  and,  to  this  end,  is  responsible  for 
collecting statistics on the animals used. It also  manages Directive 67/548/EEC 
on  the  classification  and  labelling  of dangerous  chemical  substances,  whose 
annexes define the test methods recognised by the EU. 
DG-JRC:  . 
•  ECVAM (European Centre for the Validation of Alternative Methods) has 
already  organised  14  seminars  on  the  development  and  validation  of 
alternative  methods.  Seveq  of these  seminars  concerned  the  safety  of 
cosmetic products and the reports have been published. Two other reports 
on the prevalidation and validation procedures are also available. 
•  ECB (European Chemicals Bureau) provides the technical and scientific 
support needed ~y DG XI. 
DG XXIV  /CSC (Scientific Committee on Cosmetology): 
•  DG XXIV plays a motor role in implementation, being responsible for the 
Cosmetic Products Directive, and must prepare for the Commission the 
draft measures postponing the deadline for the ban on animal tests, should 
this be necessary. 
•  The  esc  and  its  subcommittee  more  specifically  responsible  for 
alternative  methods  have  evaluated  various  documents  and  dossiers 
presented by CO  LIP  A.  They have also .  adopted a  document titled "The 
information required for the scientific evaluation of validation studies of 
,, 
H alternative tests with a view to their utilisation in evaluating the safety of 
cosmetic products" 
DGXII 
DG  XII  has  funded  various  research  programmes  on  the  development  and 
validation of alternative methods.· 
COLIPA/SCAAT (Steering Committee on Alternatives to  Animal Testing) 
Besides  preparing  dossiers  and  participating  in  numerous  studies  COLIPA 
organised an international scientific symposium on alternatives to animal tests in 
Brussels on 29 and 30 November 1995. 
I'  ' 
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•  The  American  government is  actively  seeking international  cooperation 
with a view to issuing recommendations. 
•  The  FDA  (Food  and  Drug  Administration),  which  is  the  agency 
responsible · for  the  safety  of  cosmetic  products,  has  expressed  its 
misgivings  as  regards  the  ban  on  animal  experiments  in  the 
implementation of  Directiv~ 93/35/EEC. 
OECD 
The OECD publishes guidelines on toxicity tests, approved by the Member States. 
A guideline on the in vitro control of percutaneous absorption is  currently under 
discussion. 
3  Statistics on n.nimnl experiments 
The compilation  of data  specifically  relating  to  cosmetic  ingredients  and  products  is 
difficult because the collection of data on the number of animals used for experimental 
and other scientific purposes in application of Directive 86/609/EEC is not foreseen on 
an annual basis. 
Eight  Member  States  have  declared  that  animal  tests  for  finished  cosmetic 
products  have  not  been  conducted  on  their  territory  (Italy,  Greece,  Belgium, 
Ireland, Sweden, Finland, Luxembourg, Germany). 
Six Member States have declared that animal tests for cosmetic ingredients have 
not been  conducted  on  their  territory  (Greece,  Netherlands,  Ireland,  Sweden, 
Finland, Luxembourg). 
Three  Member States  (Austria,  France,  United  Kingdom)  have  communicated 
figures while specifying in  some cases that these figures  are  unreliable and not 
interpretable. 
It should also be noted that certain Member States that do not produce ingredients may 
use  ingredients  tested  in  other  Member  States  or  in .  third  countries  and  that  certain 
ingredients may have been tested for other purposes  . 
... 
l\  \ CC/Og 
4  Conclusions and perspectives relating to the development of alternative methods 
for  the  various  toxicity  tests  used  in  the  evaluation  of the  safety  of cosmetic 
ingredients and cosmetic products. 
4-1  Ingredients 
Phototoxicity/nhotoirritancy  (skin  reaction  after  epicutaneous  application  of a 
chemicnl substance in the presence of UV radiation). This concerns in particular 
UV filters. 
The results of Phase II of the EU/COLIP  A international validation study  on in 
vitr~ photoirritancy tests have already allowed considerable progress to be made. 
A Phase m is envisaged. A supplementary study on UV filters will be necessary. 
Vnlidation should be possible in the near future. 
Percutaneous absorption 
A new guideline on in vitro tests for percutaneous absorption could be approved 
by the Member States and the OECD in  the near future. 
Skin irritation 
It is  proposed  to  evaluate  skin  irritation  of cosmetic  ingredients  on-human 
volunteers. This could be done provided prior studies concerning the toxic risk 
furnish adequate guarantees. 
Skin sensitisation 
In vitro evaluation of skin sensitisation requires more in-depth research into the 
mechanistic basis of sensitisation before a vnlidation study can be considered. 
Eye irritation 
The  results  of the  validation  studies  of alternative  methods  to  the Draize  eye 
irritation tests have been disappointing (EU/Home Office study and COLIPA) and 
none of the tests  used  met the studies'  objective.  A more  flexible  approach to 
experimentation could be encouraged by accepting a combination of  scientifically-
vnlidated  methods  and  evaluating  the  toxicity  of  the  substances  under 
consideration by comparison with appropriate benchmark substances. 
Photomutagenicity  (all  modifications of the information  content of the genetic 
material arising in the presence of UV radiation) 
Recommendations have been proposed on the criteria to be adopted with a view 
to defining the in vitro test protocols. 
Skin corrosivity 
Corrosive ingredients are not used in  cosmetic products.  However, the ECV  AM 
validation study of  in vitro tests on skin corrosivity could be used at the screening 
phase and  provide  essential  information,  before  considering  studies on human 
volunteers. Mutagenicity 
In vitro tests to  evaluate the  mutagenic potential of cosmetic ingredients are in 
current use.  In vivo tests are carried out only when the in vitro tests results are 
unsatisfactory. 
It will  probably  be  impossible  to  totally  replace  in  vivo  tests  to  evaluate  the 
systemic risk, such as tests of acute toxicity, subchronic toxicity, carcinogenicity, 
toxicity of reproduction and development, in the foreseeable future. However by 
refining the methods used it has already been possible to reduce substantially the 
number of animals used. 
4-2  Fini~hed cosmetic products 
Eye tolerance and skin tolerance of finished cosmetic products can normally be 
evaluated in vitro provided the data relating to the ingredients' toxicity and their 
physico-chemical properties are known and provide the necessary guarantees. 
Skin compatibility (absence of skin irritation) of finished cosmetic products can 
be evaluated in  man provided this is done  in  the context of strictly  controlled 
clinical studies. 
It is important to emphasise that the use of human volunteers as a way to replace 
animal tests must be considered with the greatest prudence. Such studies, whose 
ethical dimension is obvious, should only be authorised after in vitro and in vivo 
tests have demonstrated that there is no  risk of serious consequences. 
In summary:  - The  validation  of  alternative  methods  for  evaluating 
percutaneous absorption and photoirritancy in  the case of 
ingredients,  and  for  evaluating  eye  tolerance  and  skin 
tolerance in 'the case of finished products, can be envisaged 
in the near future. 
Progress in alternative methods for evaluating eye irritation, 
skin  irritation  and  skin  sensitisation  in  relation  to 
ingredients requires that additional  studies first be  carried 
out; 
The  development  of in  vitro  methods  in  the  domains 
involving a systemic risk  is not  likely  in  the  foreseeable 
future, even if it may be possible to reduce the number of 
animals used. 
v ' 
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19-20 I  A.  INTRODUCTION 
This  is  the  second  of the  reports  which  the  Commission  must  present  annually  to  the 
European  Parliament  and  Council  on  progress  in  the  development,  validation  and  legal 
acceptance of methods which could replace animal experiments for cosmetics testing. 
'The  Commission  shall present .1n  annual report to  the  European  Parliament and 
the  Council  on  progress  in  the  deJ'Ciopment,  validation  and legal acceptance  of 
altemative methods  to  those  involving  experiments  on  animals.  That  report shall 
contain precise  data  on  the number and type of  experiments relating to  cosmetic 
products carried out on animals.  The Member States shall be obliged to collect that 
information  in  addition  to  collecting  statistics  as  laid  down  by  Directive 
861609/EEC on the protection  of  animals used for experimental and other scientific 
purposes.  The  Commission  shall in particular ensure  the  development,  validation 
and legal acceptance  of experimental  methods  which  do  not  use  live  animals.' 
(Article 4(i) of  Directive 76/768/EEC,  as modified by Directive 93135/EEC). 
With the exception of the objectives, players and notion of potential risk for human health, 
which  remain  unchanged,  the  points developed  in  the  first  annual  report (COM(94)  606) 
arc reviewed: 
Clarification of the stages in  validation (B) 
Initiatives in 1995 (C) 
The state of play (D) 
Statistics on animal experiments (E) 
Conclusions (F) 
The outlook (G) 
B.  CLARIFICATION  OF  THE  STAGES  IN 
VALIDATION 
The  Commission's  main  objective  remains  that  of encouraging  the  development, 
validation and legal adoption of alternative methods which can offer the consumer a 
level of protection at least equivalent to that achieved by using animal studies. 
Validation is  the process  by  which  the reliability and relevance of a  procedure are 
established for a specific purpose. 
The  stages  involved  in  achieving  this  objective  are  more  numerous,  and  the  process  a 
more complex one, than initially foreseen. 
The first  Amden  workshop (held  in  Switzerland in  1990)  laid down the  theoretical basis 
which  is  essential  for  the  validation  process,  viz.  intra-laboratory  validation,  inter-
laboratory evaluation, the development of databases, and evaluation of the results. 
Experience with validation  studies conducted since 1990 has shown that it is necessary  to 
2 better define  the  various  objectives of the  validation  studies  and  to  integrate  new  stages 
into the process of evaluating new tests. 
ECV  AM  (European Centre for the Validation of Alternative Methods), a  unit  of the 
Environment  Institute  of  the  Joint  Research  Centre  (ISPRA),  is  at  the  hub  of  the 
discussions on  validation, and  major contributions have been made in  the following fields: 
* 
* 
* 
practical aspects of validation 
prevalidation scheme 
international discussions with ICCV  AM  (US  Inter-Agency Coordinating Committee 
for  the  Validation  of  Alternative  Methods)  and  the  OECD  (Organisation  for 
Economic  Cooperation  and  Development)  on  the  harmonisation  of validation  and 
acceptance criteria. 
Recommendations concerning  the  practical  and  logistical  aspects  of validating  alternative 
tests were  made  at the  second Amden Workshop (24-28 January  1994),  organised jointly 
by  ECV  AM  and  ERGA TI (the  European  Research  Group  for  Alternatives  in  Toxicity 
Testing), and are set out in  ECVAM workshop report No 5. 
Validation of  alternative methods used for diflCrent purposes 
Validation  of alternative  tests  can  be  conducted  with  four  mam  types  of objectives  m 
mind.  A distinction is made between: 
1.  Validation of alternative procedures for the use in  non-regulatory studies. 
2.  Validation of alternative tests for inclusion as part of regulatory guidelines. 
3.  Validation of alternative tests to replace existing guidelines. 
'  4.  Validation of alternative tests which are designed to provide part of the information 
required by a regulatory guideline. 
Stages in the evaluation of  new tests 
1.  Development of n test nnd production of n protocol 
The  criteria  taken  into  consideration  in  developing  a  test  mainly  comprise  a 
description of the  basis of the  method,  the definition of its scientific objective,  the 
specification of its biological endpoint, and the expression and interpretation of the 
results,  via a prediction model (PM). 
The  prediction model must enable  the  result obtained  with an  alternative  method 
to be converted into a correct prediction of in vivo toxicity. 
The  prediction  model  is  critical  for  the  success  of a  validation  programme.  It 
enables a clearly defined hypothesis to  be tested and an objective evaluation of test 
performance, and it serves as a guide for planning the validation study. 
2.  Prcvalidntion 
3 Experience  has  shown  that  the  outcome of large and  expensive  validation  studies 
can  be  compromised  if their  managers  do  not  insist  that  optimised  test  protocols 
and  proof  of  their  performance  are  submitted  before  the  start  of  the  formal 
validation study.  The objectives of prevalidation, and a scheme of the prevalidation 
process, are described in  the first  rel>ort of the ECVAM Prevalidation Task Fore~. 
The aims of prevalidation are: 
to optimise and standardise the protocol 
to evaluate the method's transferability. 
The prevalidation exercise comprises three phases: 
refinement  of the  protocol,  involving  collaboration  between  the  laboratory 
which  has  developed the  method  and  the  laboratory designated  to  optimise 
the method 
transfer  of  the  protocol,  involving  collaboration  between  the  first  two 
laboratories and  the laboratory designated for the transfer 
a  blind  study,  involving,  as  a  minimum,  participation  of  the  three 
laboratories responsible for &tudying  the protocol's performance. 
3.  Validation 
The validation stage comprises a formal  inter-laboratory study. 
The main stages are: 
study design 
selection of the tests 
selection of the laboratories 
selection and distribution of the  test materials 
collection and analysis of the results 
evaluation of the study. 
4.  Independent assessment of the conduct and outcome of the study. 
This  should  include  an  objective  evaluation  of the  value  of  the  scientifically 
validated  tests  by  comparison  with other tests,  taking  into  account  the  validation 
objectives. 
5.  Progression towards legal acceptance 
It is essential that any new method that is considered to be adequately validated as 
a  replacement  for  an  existing  method  receives  as  widespread  international 
recognition  as  possible.  For example,  the  OECD  test  guidelines  are  particularly 
important  in  this  respect, ' since  they  arc  used  for  tests  conducted  in  member 
countries in  Europe and  North America, and in Japan,  Australia and New Zealand. 
Furthermore,  under  the  OECD  Mutual  Acceptance  of Data  Agreement,  member 
countries have agreed to accept data from  tests performed according to OECD test 
guidelines,  provided  that  the  principles  of Good  Laboratory  Practice  (GLP)  are 
4 observed.  The OECD has established a procedure for  updating  test guidelines and 
for the introduction of new test methods. 
·1  C.  INITIATIVES IN  1995 
THE PLAYERS 
For  the  record,  the  players  involved  m  encouragmg  the  research,  development  and  · 
validation of alternative methods arc: 
1.  EUROPEAN UNION 
The European Commission 
Several  Commission  services  are  involved  in  issues  relating  to  animal 
experimentation and the development and evaluation of alternative methods. 
DG  XI,  Environment,  Nuclear  Safety  and  Civil  Protection  manages  and  is 
responsible  for  Directive  86/609/EEC,  on  the  protection  of animals  used  for 
experimental  or other scientific  purposes,  and  for  Directive  67  /548/EEC,  on  the 
classification, packaging and labelling of dangerous substances. 
DG- JRC,  Joint Research Centre 
ECVAM,  European Centre for the Validation of Alternative Methods 
ESAC,  ECV  AM Scientific Advisory Committee 
ECB,  European Chemicals Bureau 
DG .W~  Consumer Policy 
Unit  A1  - Products,  manages  Directive  76/768/EEC  (the  Cosmetics 
Directive) 
SCC.  the  Scientific  Committee  on  Cosmetology,  a  Commission  advisory 
committee 
DG XII,  Science,  Research and Development  funds research programmes: 
European industry 
COLIPA- Comite de Liaison Europeen des Industric Cosmetiques, des Produits de 
Toilette et de Ia Parfumerie, has set up SCAAT. 
SCAAT - Steering Committee on Alternatives to Animal Testing; supervises 
COLIPA's  validation  studies  and  coordinates  the  validation  efforts  of the 
cosmetics industry on a worldwide basis. 
5 2.  USA 
CTFA - Cosmetic, Toiletry and Fragrance Association 
3.  JAPAN 
JCIA- Japanese Cosmetics Industry Association 
4.  ORGANISATION  FOR  ECONOMIC  COOPERATION  AND 
DEVEWPMENT (OECD) 
The OECD publishes test guidelines,  as approved by  consensus among its  member 
countries. These guidelines are almost identical to the Annex V test methods of the 
EU,  and,  in association with  the  principle of Mutual Acceptance of Data,  provide 
an  opportunity  for  international  harmonisation  and  for  a  rational  approach  to  the 
application of the Three Rs. 
THE INITIATIVES 
1.  EUROPEAN UNION 
I  DG XI 
DG XI, Environment, Nuclear Safety and Civil Protection has reached agreement with 
the  Member States on  the  best approach  to  be  adopted in  gathering,  on  a bi-annual  basis, 
the  statistical  data  required  under  Articles  13  and  26  of Directive  86/609/EEC  on  the 
protection of animals used  for experimental and other scientific purposes. The table which 
the  Member States must complete includes a  figure  for  the  total  number of animals used 
for  cosmetic testing.  DG  XI  is also responsible for Directive 67/548/EEC and  for the  EU 
test  methods,  as  detailed  in  Commission  Directive  87 /302/EEC  and  in  the  Annex  to 
Commission Directive 92/69/EEC (Part B - Methods for the Determination of Toxicity). 
DG  XI  supported  the  EU/HO international validation  study  on alternatives to  the  Draize 
eye  irritation  test,  and  also  the  EU/COLIPA  international  validation  study  on  in  vitro 
phototoxicity. 
I  DGJRC 
ECVAM (the European Centre for the Validation of Alternative Methods)  is  at  the  • 
service of all the DGs concerned with the issues associated with alternative methods. 
ECV  AM  was  established  by  the  European  Commission  in  accordance  with  a 
Communication  from  the  Commission  to  the  Council  and  the  European  Parliament  in 
October 1991, and in  response  to  Article 23  of Directive 86/609/EEC,  which  stated  that: 
6 "The Commission and Member States should encourage research into the development and 
validation of alternative techniques which  could provide the  same level of information as 
that  obtained  in  experiments  using  animals,  but  which  involve  fewer  animals  or which 
entail  less painful procedures, and shall  take such other steps as they consider appropriate 
to encourage research in this field". 
ECV  AM has been set up to: 
1.  Coordinate the validation of alternative test methods at the European Union  level. 
2.  Act  as  a  focal· point  for  the  exchange  of  information  on  the  development  of 
alternative test methods. 
3.  Establish, maintain and manage a database on alternative procedures. 
4.  Promote  dialogue  among  legislators,  industries,  biomedical  scientists,  consumer 
organisations  and  animal  welfare  groups,  with  a  view  to  the  development, 
validation and international recognition of alternative test methods. 
The ECV  AM opening symposium organised at ISPRA on  18 October 1994 was devoted to 
discussion  of  the  validation  of  replacement  alternative  methods.  At  this  symposium, 
ECVAM's role in  the development,  valida'tion and acceptance of alternative tests and  test 
strategies,  including those for cosmetics testing,  was considered,  and  may  be summarised 
as follows:  · 
contribute to the  development of guidelines  via  the  validation process itself,  since 
this is  linked to the development and acceptance of pertinent and  reliable tests  for 
specific objectives; 
identify priorities, taking into account the state of the art in  specific fields; 
ensure that the alternative tests relate to  simple, distinct and well-defined biological 
outcomes whose mechanistic basis is sufficiently well known; 
p~omote a  multi-disciplinary  approach  with  a  view  to  developing  integrated  test 
strategies,  incorporating  quantitative  stmcture-activity  relationships  (QSAR), 
biokinetics and cell and tissue culture methods; 
address  the  difficulties  resulting  from  the  lack  of test  materials  with  associated 
high-quality in  vivo data; 
encourage the reevaluation of the existing guidelines and regulatory procedures; 
achieve  consensus  by  working  }Vith  the  appropriate  government,  industrial, 
academic and other bodies; 
draw  up  criteria  for  validation,  for  independent  evaluation  of  the  results  of 
validation  studies,  and  for  the  legal  acceptance  of  alternative  tests  and  tests 
strategies, through active cooperation with such bodies as the OECD and ICCV  AM 
(Inter-Agency  Coordinating Committee  for the  Validation of Alternative  Methods, 
USA). 
To date,  ECV  AM has organised  several  workshops on the  development and  validation of 
alternative  tests  and  has  published  the  reports of 14  of these  workshops.  ECV  AM has 
given priority to alternatives for cosmetics testing.  The  reports  of direct relevance  to 
evaluating the safety of cosmetics arc: 
report 2 
report 5 
report 6 
In  vitro phototoxicity testing (1994) 
Practical aspects of the validation of toxicity test procedures (1995) 
A prcvalidation study on in  vitro skin corrosivity testing (1995) 
7 report 7 
report 8 
report  11 
report  13 
Development  and  validation  of non-animal  tests  and  testing  strategies: 
the  identification  of a  coordinated  response  to  the  challenge  and  the 
opportunity  presented  by  the  Sixth  Amendment  to  the  Cosmetic 
Directive (1995) 
The  integrated  use  of alternative approaches  for  predicting  toxic  hazard 
(1995)  . 
The Three Rs:  the way  forward  ( 1995) 
Methods for assessing percutaneous absorption (published in  1996) 
Two other reports were published in  1995 ?n: 
the  validation  of alternative  test  methods  (a joint  statement  by  ECV  AM  and  the 
ECB) 
the first ECV  AM Prevalidation Task Force Report. 
ECV  AM's priorities in the field of cosmetics testing for 1995-1998 include: 
developmental toxicity 
metabolism 
corrosivity 
phototoxicity 
dermal penetration 
ocular and dermal irritation 
sensitisation 
ECB  (the  European  Chemicals  Bureau)  provides  technical  and  scientific  support  for 
DGXI on the  classification and  labelling of dangerous substances,  on notification of new 
substances,  on existing chemicals,  on export/import control of dangerous substances,  and 
on testing methods (according to Annex V of Directive 67 /548/EEC).  An effective liaison 
is being developed between the  ECB and ECV  AM with respect to replacement alternative 
test  methods,  and  modifications  to  animal  procedures  which  reduce  the  numbers  of 
animals required or lessen the suffering of any animals necessarily used in complying with 
regulations and guidelines. 
I  DG xx1v 1 sec 
DG  XXIV  Consumer  Policy,  which  manages  the  Cosmetic  Directive  (Directive 
761768/EEC),  remains the driving force and  has expanded its activities with a view to  the 
fullest  possible compliance with  the  provisions of Directive 93/35/EEC within  the agreed 
time limits. 
'  If alternative  methods  have  not  been  scientifically  validated  and  legally  accepted, 
DG XXIV  hns  been  instructed  to  prepare  for  the  Commission  draft  measures 
designed to extend the time limit for the ban on animal tests in accordance with the 
Committee  for  Adaptation  to  Technical  Progress  Procedure  (Article  10, 
Diredive 761768/EEC). 
8 This  Committee  (CATP)  is  made  up  of representatives  of the  Member  States  and  is 
chaired  by· a  Commission  representative.  The  Chairman  submits  to  the  Committee  the 
draft measures to be adopted. 
The opinion is delivered by qualified majority. 
In  compliance  with  the  new  co-decision  procedure,  the  European  Parliament  will  be 
informed at the  same  time and  under the  same conditions of all draft  measures submitted 
to the CATP. 
If  there has been insuflicient progress in developing satisfactory methods to replace 
anim1l  testing,  and  in  particular· in  those  cases  where  alternative  methods  of 
testing,  despite all reasonable endeavours,  have not been scientifically validated as 
offering an  equivalent  level of  protection  fOr  the  consumer,  taking  into  account 
OECD  toxicity test guidelines,  the  Commission  shall,  by 1 January  1997,  submit 
draB  measures  to  postpone  the  d.1te  of implementation  of this  provision,  fOr  a 
suflicient  period,  and in  any case for no less than too years,  in accordance  with 
the  procedure  laid  down  in  Article  10.  Before  submitting  such  measures,  the 
Commission  will consult the  Scientific  Committee  on  Cosmetology.  (Article  4(i) of 
Directive 761768/EEC,  as modified by Directive 93135/EEC). 
On  several  occasions  DG  XXIV  has  urged  the  Member States  to  meet  their obligations 
regarding the collection of precise data on animal experiments concerning ingredients and 
finished  cosmetic products.  The statistical data to be collected under Directive 93/35/EEC 
with regard to cosmetic products go beyond the data which  Member States must supply to 
comply  with  the  requirements  of Directive  86/609/EEC.  The  Member States  have  been 
requested to submit these more detailed data on an annual  basis. 
DG  XXIV  has  liaised  regularly  with  DG  XI  and  with  ECV AM,  and  has  facilitated 
communication between all players. 
SCC: the Scientific Committee on Cosmetology, a Commission advisory committee,  has 
been requested to deliver a scientific opinion to DG XXIV on the applicability of validated 
alternative methods for evaluating the  safety of cosmetic products for human use. 
TI1e  SCC's  subcommittee  on  alternative  methods  and  guidelines  organised  two 
working  meetings  (2  February,  11  May)  and  two  joint  meetings  with  SCAAT/COLIPA 
(19 September,  1 December) during which the following actions were developed. 
1.  Evaluation of documents and dossiers submitted by COLIPA 
In  vitro photoirrit.1tion (EUICOllPA) 
'  An  analysis  of  the  data  communicated  by  COLIPA  - viz.  the  partial  results 
published  in  the  literature,  in  regard  to  the  prevalidation  phase,  and  partial 
information on phase 2 has not allowed the sec to deliver a scientific opinion on 
the draft as a whole. 
However,  the SCC emphasises that the animal models arc inadequate for predicting 
the phototoxic effects in  man  and considers that a study of "in vitro" phototoxic 
9 potential  is  an  important  step  in  the  process  of  evaluating  the  safety  of 
cosmetic products containing UV filters. 
In  vitro percutaneous absorption (COUPA) 
After analysis of the documents presented by COLIPA,  viz.  guidelines for in vitro 
percutaneous  absorption  tests,  standard  protocols  and  a  general  overview  of in 
vitro/in  vivo  correlations,  the  sec  recommends  presenting  the  "in  vitro" 
percutaneous absorption  methodology in  a  standard manner and supplementing the 
methodology  with  intra- and  inter-laboratory  results  obtained  on  suitably  chosen 
test materials and vehicles. 
Photomutagenicity (COUP  A) 
The COLIPA  recommendations in the  final  report transmitted  to the  SCC indicate 
the criteria to be used in defining the test protocols. 
The  SCC  regrets  that  it  cannot  yet  base  the  evaluation  of the  photomutagenic 
potential of UV  filters  on validated tests,  despite the  fact  that it developed general 
criteria for realising photomutagcnicity tests in 1990 (SPC/803/90). 
2.  Information required for the scientific evaluation of the validation studies of 
the  alternative  tests  with  a  view  to  using  them  in  evaluating  the  safety  of 
cosmetic products 
Taking into consideration the problems arising in  connection with  validation of the 
alternative  methodologies,  the  SCC  considered  there  was  a  need  to  prepare  a 
document that would be of direct use for future validation studies. 
The  qualitative  and  quantitative  aspects  of the  validation  process  are  taken  into 
account in this report. The criteria selected: 
concern the scientific validation of the tests 
make it possible to measure a degree of toxicity 
are applicable to cosmetic ingredients 
involve definition of the  sta~stical analysis procedures 
The  need  to  provide  evidence  of protocol  optimisation  and  to  formalise  the  link 
between  in  vitro and  in  vivo data in  the  form  of a  mathematical relationship are 
highlighted. 
I  DG XII 
DG  XII,  Science,  Research  and  Development  funds  research  programmes,  notably 
including the development and validation of alternative methods according to Decision No 
1110/94/EC of the European Parliament and the Council of 26 April 1994 concerning the 
Fourth Framework Programme for Research and Technology Development,  which clearly 
set  out  instrqctions  as  follows:  "Whenever  possible,  experimentation  and  testing  on 
10 animals should be  replaced by  in  vitro or other methods ... 
Several  programmes  on  the  development  and  validation  of in  vitro  tests  have  been 
supported  by  DG  Xll or are  in  progress.  Some  of the  projects  could  be  of use  for  the 
cosmetic sector: 
BRIDGE- Final  report (EUR 15777, published in  1995) 
Development  of  a  predictive  in  vitro  test  for  the  detection  of  sensitising 
compounds.  · 
BIOTECH (1992-1994) 
Some projects concern in  vitro developmental toxicology. 
BIOTECH (1994-1998) 
The  work  programme  foresees  prenormative  research  on  m  vitro  alternatives  to 
animal experiments in pharmacotoxicology. 
IVTIP  (In  Vitro  Testing  Industrial  Platform):  forum  organised  to  improve  contacts 
between  technology  producers  and  users.  Two  meetings  were  organised  in  1995,  on 
progress  with  the  Fourth  Framework Programme  and  on  an  overview of progress  made 
with validation. 
I  COLIPA/SCAAT 
For each field of investigation SCAA  T has established specific working parties made up of 
various experts to implement the validation work. 
An  international scientific symposium on alternatives to  animal experiments was organised 
by  COLIPA  in  Brussels  on  29  and  30 November  1995,  with  representatives of industry, 
the  scientific  community,  the  Commission  and  the  European  Parliament,  and  animal 
protection societies. 
The  first  session,  devoted  to  VALIDATION,  emphasised  the  critical  role  of prediction 
models and surveyed ongoing validation  studies on photoirritation and  eye irritation.  The 
session ended with a round table on the perspectives of a regulatory approach. 
The second session, devoted to  DEVELOPMENT, included presentations on percutaneous 
absorption, skin compatibility and skin sen.sitisation. 
The third session,  devoted to SAFETY EVALUATION, addressed the initiatives taken by 
the  SCC  as  well  as  the  approaches  of the  British  and  German  regulatory  authorities. 
Emphasis  was  placed  on  the  importance  of providing  scientific  data  in  support  of the 
cosmetics  industry's  "in-house"  studies  and  test  strategies  for  evaluating  the  safety  of 
finished products. 
The  presentations  were  supplemented  by  a  poster  exhibition.  In  the  context  of  this 
exhibition,  a  brochure  setting  out  the  approach  of IFAW  (the·  International  Fund  for 
Animal  Welfare)  was  provided  to  the  participants.  As  there  is  clearly  no  question  of 
1 1 replacing  animal  tests  by  a  simple  in  vitro  test,  IFAW  presents  a  phase-based  strategy 
based  essentially  on  alternatives  which  focus  on  the  use  of cells  and  tissues  of human 
origin,  excluding  all  in  vivo  animal  experiments  and  recommending  in  vivo  tests  on 
volunteers. 
The  symposium  highlighted the  important role of COLIPA  (European cosmetics industry) 
in  undertaking  research  into  the  development and  validation  of alternative  methods.  The 
work being done by the major European cosmetic companies is very  substantial when one 
considers the number of animals used in cosmetic experiments and the knowledge acquired 
greatly benefits other industries. 
Moreover,  the  symposium  provided  the  different  players  involved  with  precise  scientific 
information  and  gave  rise  to  an  interesting  exchange  of views.  A  joint  approach  of 
industry  and  the  Commission  was  called  for,  so  that  animal  tests  in  the  fields  of skin 
compatibility, photoirritation and percutaneous absorption can rapidly be replaced. 
2.  USA 
The US  government is keen on international cooperation to  recommend an  approach and 
to  define  the  criteria  for  the  regulatory  adoption  of new  alternative  methods,  clearly 
establishing  the  conditions  under  which  these  methods  are  used  (biological  outcomes, 
relevance  for  classes  of  substances,  etc.).  ICCVAM  organised  a  workshop  on  the 
validation and regulatory acceptance of  alt~rnative toxicological testing methods,  sponsored 
by  the  National  Institute  of Environmental  Health  Sciences  (NIEHS)  and  the  National 
Toxicology Program (NTP), in  December 1995  in Arlington,  Virginia. The purpose of the 
workshop  was  to  discuss  the  draft  ICCV  AM  report  containing  recommendations  about 
criteria  and  processes  for  the  validation  and  regulatory  acceptance  of new  and  revised 
toxicological testing methods. 
The  Food  and  Drug  Administration  (FDA)  is  the  US  agency  responsible  for  cosmetics 
safety.  The FDA has interactive relations with  the public and private agencies involved in 
the development and validation of alternative tests, and focuses on  methods which generate 
reliable scientific data. 
The  FDA  has  misgivings  about  the  prohibition  of  animal  experiments  in  the 
implementation of Directive  93/35/EEC.  Certain  cosmetics  manufactured  in  the  EU 
might  not satisfy  the  safety  requirements (for health)  laid down by  the  US  FDCA (Food, 
Drug and Cosmetics Act). 
3.  JAPAN 
The Japanese  Ministry  for  Health and  Welfare  (MHW)  is responsible  for  testing  and  test 
guidelines in Japan. Japanese research groups are particularly involved in the validation of 
alternatives  to  the  Draize  eye  test.  The  acceptance  of the  alternatives  depends  on  their 
specific role in the evaluation of eye irritation (screening or replacement; individual test or 
batteries of tests).  JCIA  considers that it would  be  difficult to  recommend  for  regulatory 
testing  purposes  for  evaluating  the  safety  of cosmetic  products,  a  test  or test  battery 
whose predictivity was less than  that of in vivo methods. 
12 4.  OECD 
In  October  1994,  the  5th  meeting  of  the  National  Coordinators  of  the  OECD  Test 
Guidelines Programme agreed that an attempt should be made to  internationally harmonise 
the various published and advocated concepts for the validation of alternative test methods. 
In  view of the international debate on the issue, it was considered timely  for the OECD to 
step in and provide a platform for all parties involved,  through which it might be possible 
to  reach  international  consensus  on  validation  and  acceptance  criteria.  The  National 
Coordinators  emphasised  that  existing  proposals  should  be  used  as  the  basis  for  an 
internationally acceptable approach, rather than the development of yet another concept. In 
this  respect,  the  work of centres  such  as  CAAT  (Johns  Hopkins  University  Center  for 
Alternatives to  Animal  Testing)  in  the  US,  ECVAM  in  the  EU,  ERGATI, and  various 
national centres and committees (e.g.  FRAME in the UK,  IRAG and ICCVAM in the US, 
NCA  in  the  Netherlands,  SlAT  in  Switzerland,  and  ZEBET  in  Germany)  was  well-
recognised. 
The National  Coordinators agreed  that an  OECD Workshop would be the  best approach, 
since such a meeting would offer ample opportunity for all parties having an interest in  the 
subject  to  discuss  the  issue  and  to  seek  consensus.  Furthermore,  it  was  considered  of 
crucial  importance that  member countries would  include  in  their nominations  individuals 
having responsibilities in the regulatory area. Sweden offered to host the workshop. 
A Steering Committee was established in ianuary 1995  to advise the OECD Secretariat on 
the  scope  and  structure  of the  Workshop,  and  to  assist  in  the  development  of the 
programme  for  the  Workshop,  which  was  scheduled  for  22-24  January  1996,  in  Solna, 
Sweden. ECV  AM and ZEBET were represented on this Steering Committee. 
I  D.  TilE STATE OF PLAY 
METHODS UNDER DEVELOPMENT AND VALIDATION 
Sldn sensitiSlltion 
Sensitisation  is  an  area  of considerable  research  and  is  extremely  relevant  to  cosmetics 
safety.  An  interesting  approach  to  the  in  vitro  evaluation  of skin  sensitisation  was 
presented at the  symposium organised by  COLIPA (29-30 November 1995).  An ECVAM 
workshop  on  skin  sensitisation  was  held  during  1995,  the  report  of  which  will  be 
published in  1996. 
The  chemical  structures  and  senstttsmg  potentials  of  various  compounds  have  been 
extensively  examined  and  expert  computer  systems,  such  as  DEREK  (Deductive 
Estimation of Risk  from  Existing  Knowledge),  are being developed  to identify  structural 
alerts associated with skin  sensitisation potential.  A possible predictive approach could be 
based  on  measurement  of the  molecular  signals  induced  in  cell  cultures  by  sensitising 
substances. 
13 Notably in  this domain it should be emphasised that prediction of sensitisation potential in 
humans remains a major problem because of the inter-individual variability in  response. 
Photomntsgenicity  Validation (OOUPA) 
Since  1990,  COLIPA  has  submitted  dossiers on UV  filters  containing photomutagenicity 
data obtained from different types of tests.  · 
COLIPA organised a ring test to define a suitable protocol by  using two substances whose 
photomutagenic potentials were known,  and which  were activated by UV-A radiation and 
different  bacterial  strains.  The  results  of this  ring  test  have  made  it  possible  to  draft 
recommendations on  the  criteria  for  selecting  bacterial  strains or cell  cultures,  the  solar 
simulator, the  technique of sample irradiation,  UV  radiation doses,  doses of substances to 
be tested,  and  the  use  of positive controls.  It is  difficult to plan a validation study in  the 
absence of in vivo  reference data. 
Percutnneous nhsorption 
ECVAM, COLIPA and the OECD have collaborated to facilitate the international adoption 
of a testing guideline on in vitro percutaneous absorption. 
Pbo~oirritntion!p!Jototoxidty: Validation - phase II (EU/OOUPA) 
ECV  AM  and  DG  XI  arc represented  on  the  Management Team  for  the  study,  which  is 
being  coordinated  by  ZEBET,  and  is  examining  the  possibility  of  a  supplementary 
validation study designed to predict the photoirritant potential of UV filters. 
In  the  first  (prevalidation)  phase  of the  study,  analysis  of the  results  obtained  in  a  cell 
viability  test  made  it  possible  to  determine  a  photoirritancy  factor  for  distinguishing 
photoirritant  substances  from  non-photoirritant  substances.  The  objective  of the  second 
(validation)  phase,  planned as  a  blind  trial,  was  to  determine  whether a  cell  toxicity  test 
and a test measuring cell damage (the NRU
1 and the combined test RBC
2 (photohaemolysis 
+  haemoglobin  oxidation])  could  correctly  predict  the  photoirritant  potential  of  32 
chemical substances, which have been  administered systemically or topically in man. 
The preliminary results of phase  II,  which ended in  1995,  are confined  to  the  NRU  test 
used  in  all  the  laboratories.  The  RBC  protocol  was  used  only  in  three  laboratories. 
Supplementary statistical evaluations were carried out by an independent biostatistician and 
will be available during the first half of 1996. 
2JmC:  red blood cell haemolysis test; used to evaluate damage to the cell membranes 
14 Eye  initntion:  linn/ rcpvrl on  tlle  EC!HO stud]'  on  altemntircs  to  U1e  Dmize  e.re 
inillltion test 
The  objective  of this  study  was  to  determine  whether nine  alternative  tests,  alone  or in 
combination,  could  replace  the  Draize  test  for  severely  irritant  test  materials or evaluate . 
the  irritant potential of chemical  substances,  with or without  regard to  the chemical  class 
and over the entire range of measurable potentials. 
A  total  of 60  chemical  substances  were  analysed  independently  in  37  laboratories.  The 
results were compared with the MMAS (modified maximum average score) obtained in the 
Draize test and submitted for statistical evaluation. 
With the exception of predicting the irritant potential of surfactants,  none of the nine tests 
achieved any of the envisaged objectives. 
Many valuable  lessons were  learned  during  this  study,  which  were  taken  into account  in 
the  planning of the  COLIPA  study.  They also led  to  the  ECVAM  workshop on practical 
aspects of validation,  and  to  the  development of the  ECV AM  prevalidation  scheme.  The 
variablility of the  in  vivo data was  identified as a  major obstacle for  the  establishment of 
the relevance and reliability of the in  vivo tests. 
Eye initntion: VnlidfJtion (CYJUPA) 
The  validation  exercise was  conducted  on  23  cosmetic  ingredients  (surfactants,  alcohols, 
preservatives), of which 20 were the  same as those tested in  the EC/HO study, and on  32 
cosmetic  formulations  (with  a large  range of physico-chemical  forms).  The test  materials 
were tested in vivo in compliance with OECD guideline 405. 
The  specific objectives of this  study  were to determine whether the  data obtained on the 
basis of 10 in  vitro protocols currently  used  in  the  cosmetic  industry  (of which  five  had 
also been evaluated in the EC/HO study): 
correlate acceptably with the MMAS (modified maximum average score); 
correlate acceptably  with  the  individual  scores and  recovery  times,  such  as  those 
described in OECD guideline 405; 
correctly predict the eye irritation potential in the rabbit on  the basis of algorithms 
for the alternative method. 
For the  first  time  in a  validation  study,  prediction  models  (PMs)  were  laid  down 
before the start of the study. They define precisely the biological outcomes obtained for 
each in vitro model and how to convert each in vitro biological outcome into a prediction 
of eye  irritation  potential.  The  PMs  used  in  this  study  are  based  on  historical  data 
available for the ingredients and formulatiQns of interest to the cosmetics industry,  notably 
for substances with a low to moderate irritation potential. 
The programme did not permit complete validation because of the small number of 
laboratories  that  participated  in  assnys  specific  to  the  programme.  None  of the 
methods tested can yet validly replace the Draize eye irritation test. 
15 The  reliability  of the  PMs  was  evaluated  by  determining  whether  the  inter-laboratory 
results  were ·reproducible  and  whether  the  data  were  distributed  within  the  prediction 
intervals of the predefined PMs. 
The RBC test showed good inter-laboratory reproducibility and also satisfied the reliability 
criteria. 
Three of the  protocols  tested  conformed  reasonably  with  their prediction  models  (FLT
3
, 
RBC,  TEA 
4
),  but  supplementary  studies  are  necessary  to  resolve  several  technical 
problems associated  with  the  PMs before  final  conclusions about  their performances can 
be drawn. 
This validation study highlights the importance of the availability of good-quality in 
vivo data.  · 
The  in  vivo  data  available  are  adequate  for  evaluating  the  risk.  However,  in  order  to 
compare  the  in  vivo  and  in  vitro data,  the  two  sets of data should  theoretically  have  as 
small  a  variability  as  possible,  to  permit  precise  statistical  evaluation.  Experience  has 
shown that this is not always the case. 
Examination of the results indicate that certain PMs could be refined and tested in a future 
study. 
Sldn convsivity: Prevalidntion (ECV  AM) 
Four  skin  corrosivity  tests  arc  being  evaluated  and  optimised  (TER  - rat  skin 
transcutaneous  electrical  resistance  assay,  CORROSITEX,  Skin
2  and  EPJSKIN)  with  a 
view to planning a formal  validation study for 1996. 
Sldn COlllfXltibility (COUP  A) 
Skin compatibility is defined as the absence of skin irritation in nonnal conditions of 
use and in reasonably foreseeable conditions of improper use. 
Seven  COLIPA  member  companies  evaluate  the  skin  compatibility  of  their  finished 
products  in  man  under  controlled  conditions,  because  the  irritation  potentials  of most 
cosmetic products are very low. 
COLIPA  has  developed  guidelines  for  evaluating  the  compatibility  of finished  cosmetic 
products on human skin: 
3FL  T: fluorescein leakage test:  measures the damage caused to a cell barrier  . 
.trEA: tissue equivalent assay; measures the time required to cause a 50%  reduction in the  viability of 
cells in  reconstituted human skin 
16 taking  ethical  requirements  into  account,  studies  on  man  must  be  conducted  m 
accordance with the  Helsinki Declaration (1964,  1989); 
a prudent approach to tests, stage by  stage, is essential; 
prior knowledge of the  composition and  stability of the products tested,  as well  as 
prior evaluation of toxicity data on the product ingredients,  is necessary. 
Guidelines on the skin compatibility of cosmetic ingredients are currently being developed. 
Hui1J!ln  Jvlunteer studies (ECV  AM) 
Human  volunteer  studies  are  often  listed  along  with  other  replacement  alternatives  for 
animal  tests.  The  ethical,  legal,  safety,  logistic  and  scientific  problems  associated  with 
such  studies  are being  investigated  by  ECV  AM,  in  collaboration  with  the  University  of 
Pavia, the University of Nottingham, and a number of cosmetic companies. 
I  E.  STATISTICS ON ANIMAL EXPERIMENTS 
The collection of data on  the  number of animals used  for experimental or other scientific 
purposes pursuant  to  Articles  13  and  26 of Directive  86/609/EEC  is  not  planned  on  an 
annual basis. 
This  partly  explains  the  difficulties  encountered  m  collecting  annual  data  specifically 
concerning cosmetic ingredients and products. 
However,  the Commission has on numerous occasions urged the  Member States to obtain 
the statistics required, as is recalled in relation to the activities of DG XXIV and DG XI. 
(1)  Eight Member States have declared that animal tests for  finished cosmetic products 
have  not  been  carried  out  on  their  territory  (Italy,  Greece,  Belgium,  Ireland, 
Sweden, Finland,  Luxembourg, Germany). 
(2)  Six  Member States have  declared  that  animal  tests  for cosmetic  ingredients  have 
not  been  carried  out  on  their  territory  (Greece,  Netherlands,  Ireland,  Sweden, 
Finland, Luxembourg). 
(3)  Only three Member States (Austria,  France,  United  Kingdom)  have communicated 
figures  relating  to  the  number of animals  used,  while  pointing  out  however  that 
these  figures  cannot  be  interpreted  and  that  uncertainties  remain  as  to  their 
correspondence  to  reality.  Under  these  circumstances  this  report  cannot  present 
comparative tables consisting of numerical  data because such  a table would give a 
false  view of reality. 
(4)  As  regards the declarations that tests have  not  been  carried out,  it should also  be 
noted that certain Member States that do not produce ingredients may of course use 
ingredients  tested  in  other  Member  States  or in  third  countries  and  that  certain 
ingredients used for cosmetic products may  have been tested for other purposes. 
17 The Commission strongly regrets that it does not have more precise data at this  moment, 
but it depends on the Member States for the collection of these data. 
I  F.  CONCLUSIONS 
Progress during  1995  with  regard  to  alternative  test  methods and  their  validation  can  be 
summarised as follows: 
1.  The report on Phase II of the EU/COLIPA international validation study on in  vitro 
tests  for  phototoxicity  (photoirritancy)  wi1l  be  made  available  in  1996,  but  it  is 
already  dear  that  the  validation  of  the  NRU  cell  culture  test  has  been  very 
successful.  Those  involved  in  the  study  are  confident  that  an  acceptable  OECD 
guideline can be drafted within the  next two years, i.e. after the  final  report on the 
study has been published and minor refinements to protocols have been made. 
2.  Experience in  European industry on the critical issue of percutaneous absorption 
has led to a concrete proposal for an OECD guideline for an  in vitro test.  ECV  AM 
and COLIPA are working  with  the OECD and others,  to  facilitate  the adoption of 
an in vitro test guideline by the OECD Member Countries. 
3.  The  results  of the  EC/HO  international  validation  study  on  alternatives  for  the 
Draize  eye  irritancy test  were  disappointing,  in  that  none  of the  tests  met  the 
goals of the  study.  However,  much  of value  was  learned  during  this  study,  as  a 
result of which the quality of future validation studies will be markedly improved. 
4.  The first phase of the  COLIPA evaluation of alternatives to  the Draize eye  test, 
conducted on  a  more-limited  range of materials  than  the  EC/HO study,  produced 
more-promising  results,  and  showed  the  value of incorporating  prediction  models 
into test protocols. 
5.  As a result of a COLIPA study,  recommendations have been drafted on criteria to 
be adopted in defining in vitro test protocols for photomutagenicity. 
6.  As· a  result  of another  COLIPA  initiative,  guidelines  on  the  skin compatibility 
testing of cosmetic products and their ingredients in man have been developed. 
7.  The use of human volunteers as a replacement alternative deserves further scrutiny, 
but it must be emphasised that such studies should only be conducted after results 
from  previous in  vivo and/or in vitro studies permit avoidance of the risk of any 
serious consequences. 
8.  Validation  has  turned  out  to  be  even  more  difficult,  more  time-consuming  and 
more  costly  than  had  been  expected.  Indeed,  discussions  are  still going on about 
18 what validation actually  means and how  the relevance and  reliability of alternative 
methods can best be established.  ECV AM  is at the  heart of these discussions,  and 
particularly important contributions have been made in a number of ways. 
9.  The  ECVAM  prevalidation  scheme,  which  is  currently  under  international 
evaluation, is likely to improve the success rate of validation studies, and to reduce 
the time needed to conduct them,  as well as their cost. 
10.  International  discussions  have  taken  place  within  Europe,  and  also  with  the  USA 
and  Japan,  on  the  harmonisation  of criteria  for  the  validation  and  acceptance  of 
replacement alternative test methods. 
I  G.  THE OUTLOOK 
I.  The  emergence  of more-realistic  expectations  of the  validation  process,  and  the 
success of international discussions on criteria for  the  validation and acceptance of 
replacement alternative methods can be expected to result in  substantial progress in 
the future. 
2.  After the conclusion of a further small  study on  chemicals of particular concern to 
the  sec,  it  can  be  expected  that  a  draft  regulatory  guideline  for  in  vitro 
phototoxicity  testing  will  be  produced  and  proposed  for  acceptance  by  the 
regulatory authorities. 
3.  It is hoped that a new guideline on in  vitro tests for percutaneous absorption will 
shortly be accepted by the EU Member States and the OECD Member Countries. 
4.  An  acceleration  of  progress  toward  the  development  of  standardised  and 
appropriate in  vitro methods for detecting sensitisation potential can be expected. 
5.  A reconsideration of what is expected of eye irritancy tests (in  vivo and in vitro) 
will  be  essential.  Meanwhile,  a  more  flexible  approach  to  testing  could  be 
encouraged,  for  example,  by  accepting  the  evaluation  of the  toxicities  of new 
products and ingredients by  comparison with knowledge of appropriate benchmark 
substances. 
6.  Greater usc could be made of the fact that the eye tolerance and skin tolerance of 
finished  cosmetic  products  can  be  evaluated  in  vitro,  provided  one  crucial 
condition  is  met,  viz.  prior  knowledge  of the  toxicity  data  pertaining  to  the 
ingredients  and  their  physico-chemical  properties.  In  addition,  the  skin 
compatibility  of finished  cosmetic  products  can  be  evaluated  in  the  context  of 
strictly controlled clinical studies. 
19 7.  A successful outcome can be expected for the ECVAM validation study on tests for 
skin corrosivity,  which  could  then  be  used,  for  example,  to  provide part of the 
information considered essential before human  volunteer studies can be considered 
permissible. 
8.  There  will  be  greater  emphasis  on  the  integrated  use  of  various  different 
approaches  (e.g.  computer-based  predictions,  in  vitro  tests),  and  on  hierarchical 
testing  strategies,  to  reduce,  refine  and  replace  the  use  of animals  for  testing 
purposes. 
The Sixth Amendment to  Directive 76/768/EEC provides a unique opportunity for sensible 
progress toward the  replacement of animal testing in  the  field  of cosmetics.  Such progress 
is being made, but its continuation will depend upon the maintenance of good relationships 
and  effective collaborations between all  the parties involved,  i.e.  the  Commission and  its 
advisory  committees,  the  Member  States,  the  cosmetics  industry,  and  the  regulatory 
authorities. 
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